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CDK4 Mutation in an Italian Melanoma-Prone Family: Fifth Case
Described Worldwide
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Grammatico^ and C Catricala*
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Gallicano – IRCCS, Rome, Italy and ^Medical Genetics, University ‘‘La Sapienza’’
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CDKN2A is considered the major gene for melanoma susceptibility even if genetic
alteration of this gene have been detected in only 20–30% of melanoma-prone
families. This observation allowed to understand that other genes have to be
discover. CDK4 gene is located in the 12q13 region, contains 8 exons and spans 5
kb and the protein is a member of the Ser/Thr protein kinase family. Mutations of
CDK4 seems to be a rare cause of melanoma susceptibility and to date only four
families carrying a mutation in the 24 codon of this gene, two American, one
French and one Norwegian, were described (Zuo et al. 1996; Soufir et al. 1998,
Molven et al. 2005). We describe an Italian melanoma-prone family, in which was
excluded the presence of any CDKN2A mutations, where it was identified an
Arg24His CDK4 mutation in four patients affected by cutaneous melanoma. At the
first observation, in 1995, the proband presented a cutaneous melanoma at the age
of 59 years, and subsequently his sister developed a cutaneous melanoma at the
age of 45 years old. The proband had also multiple, clinically atypical, nevi. All the
family members were born in Rome and mainly live in the centre of Italy. We are
now performing molecular analysis in some unaffected individuals from the same
family. A follow-up report included 11 subjects over three generations and we are
also analyzing the possible association with other tumors present in some members
of this family.
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GRM1 Gene Could be Related to Human Melanoma Susceptibility
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Introduction. Recent data obtained from a mouse model indicated that the ectopic
expression of GRM1 gene is sufficient to transform melanocytes and give rise to
malignant melanoma in vivo. In addition, it has also been reported that the GRM1
gene is aberrantly expressed in human melanomas.
Objectives. To elucidate whether the GRM1 gene could have a role in human
melanoma susceptibility.
Patientes, material and methods. 274 melanoma patients and 363 unselected and
unrelated controls were genotyped with three single nucleotide polymorphisms:
rs854145, rs362962 and rs6923492; located at 5´ upstream, intron 3 and exon 8 of
the GRM1 gene respectively. To perform sample genotyping we used pyrosequen-
cing techniques.
Results. We observed a higher frequency of patients under age 60 carrying the G
allele of rs362962 than those observed in controls (OR¼1.61 C.I.¼ [1.07–2.40]
p¼ 0.020). The majority of these patients presented the primary tumour in the
trunk, legs or arms (OR:1.38 C.I.:[0.97–1.95] p¼ 0.068).
Conclusion. Our results suggest that the GRM1 gene could contribute to the
development of early-onset melanoma in such locations.
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Resistance of Melanoma Cells to TRAIL Depends on Downregulation of
Initiator Caspases and DR4 Rather Than on Activation of NF-kB
BM Kurbanov, LF Fecker, W Sterry and J Eberle
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TNF-related apoptosis-inducing ligand (TRAIL) attracts considerable attention as a
novel anticancer agent since its advantage to kill selectively tumor cells. However,
its efficiency may be diminished by occurring resistance in cancer cells. The
mechanisms of TRAIL resistance in melanoma are still unsolved. Our present data
are based on TRAIL-R1/DR4-expressing and non-expressing melanoma cell lines as
well as on an established cell culture model for TRAIL resistance and regained
TRAIL sensitivity. TRAIL-induced activation of NF-kB, a prominent candidate for
mediating TRAIL resistance, was seen only in apoptosis sensitive melanoma cell
lines through DR4 whereas, TRAIL failed to activate NF-kB in DR4-negative (DR5-
positive) melanoma cells regardless their sensitivity. Activation of NF-kB by TRAIL
was not associated with any changes in the expression of the antiapoptotic proteins
c-FLIP, Bcl-xL, XIAP, Survivin or Livin. Rather, TRAIL induced downregulation of
DR4 in one of the cell lines, and this effect was prevented by proteasome inhibition
(LLnL). In general, LLnL-mediated TRAIL-sensitivity was independent of NF-kB
activation in melanoma cells. Also in selected, TRAIL-resistant melanoma cells,
neither an increase in TRAIL-induced NF-kB activation nor an increased expression
of antiapoptotic proteins was found. However, significant downregulation of the
expression of caspase-8, caspase-10 and of DR4 was characteristic for selected,
TRAIL-resistant melanoma cells, and sensitivity was largely retained after
exogeneous overexpression of these factors. Thus, initiator caspases and DR4
may become useful markers for predicting melanoma sensitivity to TRAIL, and
strategies, which result in their upregulation may be suitable for combination
treatments.
FC04
Neurotrophins (NT) Modulate Survival and Chemotaxis in Metastatic
and Primary Melanoma Cell Lines through their High-Affinity
Receptors Trk
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NT are a family of structurally and functionally related molecules including nerve
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3
(NT-3) and NT-4. NT act through two receptors, the low-affinity receptor p75
(p75NTR) and the high-affinity receptor Trk. It has been shown that NGF and NT-3
are important in the progression of melanoma to the brain-metastatic phenotype. In
this study, we evaluated the expression and function of NT in metastatic and
primary melanoma cell lines. Metastatic and primary melanoma cell lines A375,
Mewo, Me272, WM115, WM266-4 and SK-MEL-28 express all NT. In particular,
melanoma cell lines secrete very high levels of NT-3, high levels of NT-4 but low
levels of NGF and BDNF. Melanoma cell lines also express the low affinity NT
receptor p75NTR at different levels. Moreover, metastatic and primary melanoma
cell lines also express the high-affinity NT receptors (Trks), as shown by RT-PCR.
No effect of NT on melanoma cell growth was observed. On the contrary, addition
of K252a, a phosphorylation inhibitor of Trks, blocked cell line proliferation.
Moreover, using NT specific blockers (TrKA, TrkB, TrkC/Fc chimera), deprivation of
NT3 arrests proliferation of all cell lines. The deprivation of NGF arrests
proliferation of both WM115 and Skmel28, while deprivation of NT-4/BDNF
arrests proliferation of WM115 only. Finally, all NT induced the chemotaxis of
Skmel28, while NT4 and BDNF stimulated the chemotaxis of WM266-4. These
results seem to suggest that NT and their receptors may be involved in the growth,
invasion of melanoma cells thus contributing to melanoma progression.
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Enhancement of Vaccine-Mediated Antitumor Immunity in Melanoma
Patients by Dacarbazine Treatment
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Although immunotherapy is considered an attractive antitumor strategy, the limited
clinical responses underline the importance of designing novel strategies to
overcome tumor escape. Preclinical studies demonstrated that non-myeloablative
treatment enhances the activity of antitumor vaccines. Ten HLA-A2 stage II/IV
melanoma patients, with no evidence of disease, were enrolled in a phase I–II
clinical trial and randomly assigned to one of two treatment groups: 1) Vaccine:
Montanide, Melan-A/MART-1:26–35(27L), gp100:209–217(210 M), IFN-alpha; 2)
Vaccine combined with dacarbazine 800 mg/mq. No major toxicity was observed
in either treatment group. IFN-gamma ELISPOT assay and tetramer analysis were
used to monitor immune responses before and at different times during vaccination,
in either ex-vivo or in vitro expanded CD8þ T cells. A strong ex-vivo expansion of
peptide-specific CD8þ T cells was observed only in patients treated with
dacarbazine plus vaccine (4/5 patients). Moreover, in-vitro stimulation of CD8þ T
cells demonstrated that patients receiving the combined treatment developed a
peptide-specific immune response and ability of specifically lysing tumor cells
consistently higher than the group treated with vaccine alone. Among the five
patients treated with vaccine alone, four went into progression. In contrast, 3 out of
5 patients treated with vaccine plus darcabazine are, presently, disease free. These
results suggest that the efficacy of cancer immunotherapy can be synergistically
enhanced by combining cancer vaccines with conventional cancer treatment. The
use of dacarbazine in combination with vaccine could represent a novel strategy in
the treatment of melanoma patients. Supported by Italian Ministry of Health,
project 3AO/F.
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Immunotherapeutic interventions such as vaccination with dendritic cells are a
promising treatment option in metastasized melanoma. Due to relative small
patient cohorts in vaccination trials and significant differences between the stage
and kinetic of disease of each patient, median time to progression and median
survival not necessarily reflect the efficiency of a vaccination. It is therefore
obligatory to perform an accurate monitoring of immune responses in each patient
under vaccination therapy. Here we demonstrate in comparison 1) by ELISPOT and
2) by mixed lymphocyte/peptide culture (MLPC) and tetramer staining, that after
four vaccinations with peptide loaded dendritic cells patients present significant
immune inductions (CTL and Th induction) against the vaccinated tumour antigens
(MAGE-10.A2, gp100.A2, NY-ESO-1.A2 and Mage-3.DP4). Whereas in INF-
gamma/IL-4-ELISPOT functional information is obtained, MLPC with tetramers
allows an estimate of the minimal precursor frequency of tumour specific CD4- and
CD8-positive T-cells in the blood. In the MLPC we observed a rise of percentage of
tumour-peptide specific T-cell precursor of total CD8þ T-cells from 40.22x106
(pre-vaccination) to 4220x106 (post-vaccination). Additionally cells amplified by
MLPC can be applied in functional assays and phenotype studies can be performed.
Comparing ELISPOT and MLPC shows a good correlation with regard to monitoring
immune responses during vaccination therapies.
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